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In the present study, the clinician decided
whether the CNS isolate represented a true
bacteraemic episode. This did not change treat-
ment decisions, or disrupt patient care. There was
no evidence for increased resistance trends, nor
did vancomycin utilisation increase more than
would be expected, since there were also more
patients with central venous catheters, more
foreign body-related infections, and more infec-
tions overall caused by CNS, Enterococcus spp.
and methicillin-resistant Staphylococcus aureus.
Increased vancomycin use cannot, therefore,
result solely from the absence of routine AST of
blood culture CNS isolates. Ongoing review has
validated this practice and it is now laboratory
policy. The laboratory is now also performing AST
only upon request for CNS isolates from central
venous catheters in the same patient populations.
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Activity of ﬁve quinolones, three macrolides
and telithromycin against 12 Haemophilus
inﬂuenzae strains with different resistance
phenotypes
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ABSTRACT
Gemiﬂoxacin MICs for 12 Haemophilus inﬂuenzae
strains with different resistance phenotypes were
0.001–0.015 mg ⁄L. Gemiﬂoxacin was bactericidal
against all 12 strains after 24 h at 2 · MIC.
Ciproﬂoxacin, levoﬂoxacin, gatiﬂoxacin and
Corresponding author and reprint requests: P. C. Appelbaum,
Hershey Medical Center, PO Box 850, Hershey, PA 17033, USA
E-mail: pappelbaum@psu.edu
1040 Clinical Microbiology and Infection, Volume 11 Number 12, December 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 1035–1047
moxiﬂoxacin had MICs of 0.008–0.03 mg ⁄L and
similar kill kinetics. Macrolides and telithromycin
had unimodal MICs (1.0–8.0 mg ⁄L), except for
two strains without efﬂux systems (0.0125–
0.5 mg ⁄L) and two with efﬂux systems and
ribosomal protein mutations (> 64.0 mg ⁄L), and
were bactericidal against eight to ten strains
tested at 2 · MIC after 24 h.
Keywords Haemophilus inﬂuenzae, kill kinetics,
macrolides, quinolones, resistance, telithromycin
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Haemophilus inﬂuenzae, together with Streptococcus
pneumoniae and Moraxella catarrhalis, is a major
cause of community-acquired respiratory infec-
tions in children and adults, including pneu-
monia, acute exacerbations of chronic bronchitis,
sinusitis and otitis media [1–6]. In countries
where the H. inﬂuenzae type b vaccine is used
widely, such as the USA, H. inﬂuenzae type b has
been replaced in many infections by untypeable
H. inﬂuenzae strains [2–4,7].
The major resistance mechanism inH. inﬂuenzae
in the USA and Europe is b-lactamase production
(TEM-1, ROB-1). The incidence of b-lactamase-
negative ampicillin-resistant strains in the USA is
< 1%, but is higher in Japan [8] and France [9]. Of
the b-lactams available for treatment of H. inﬂuen-
zae infections, ceﬁxime and cefpodoxime are the
most active from both an MIC and pharmacoki-
netic ⁄pharmacodynamic viewpoint, followed by
amoxycillin–clavulanate and cefuroxime. Among
macrolides and azalides, azithromycin has the
lowest MIC for H. inﬂuenzae, followed by erythro-
mycin and clarithromycin [3,4,10]. However, the
pharmacokinetic and pharmacodynamic proper-
ties of these compounds, and the results of double-
tap otitis media studies, cast doubt on their clinical
efﬁcacy against H. inﬂuenzae [3–6]; additionally, a
macrolide efﬂux mechanism has been described in
‘baseline’H. inﬂuenzae strains, and added ribosom-
al protein mutations in macrolide-hyper-resistant
strains [11–13]. Quinolone resistance in H. inﬂuen-
zae is still very rare [7,10,14].
To cast further light on the utility of quinolones
vs. macrolides and ketolides for the treatment of
community-acquired respiratory tract infections,
macrobroth and time-kill methodology was used
to examine the activities of ciproﬂoxacin, levo-
ﬂoxacin, gatiﬂoxacin, moxiﬂoxacin, gemiﬂoxacin,
erythromycin, azithromycin, clarithromycin and
telithromycin against 12 H. inﬂuenzae strains with
different b-lactam and macrolide resistance phe-
notypes. Of the 12 strains tested, two each were
b-lactamase-positive, b-lactamase-negative, b-lac-
tamase-negative and ampicillin-resistant with
mutations in PBP3 [8], b-lactamase positive and
amoxycillin–clavulanate-resistant (PBP3 muta-
tions plus TEM-1 production) [8], macrolide-
hyper-susceptible without a carbonyl cyanide
m-chlorophenylhydrazone-dependent macrolide
efﬂux mechanism, and macrolide-hyper-resistant
with an efﬂux mechanism plus one or more
ribosomal protein mutations [11–13]. m-Chloro-
phenylhydrazone is amitochondrial protonophore
that uncouples oxidative phosphorylation, and
thus inhibits efﬂux [11–13]. Strains were stored
frozen in double strength skimmed milk (Difco,
Detroit, MI, USA) before testing. Drugs were
obtained from their respective manufacturers.
Time-kill studies were performed as described
previously [10,15–17]. Glass tubes containing
5 mL of freshly made Haemophilus test medium
containing doubling antibiotic concentrations
were inoculated with c. 5 · 105 to 5 · 106 CFU/
mL and incubated at 35C in a shaking water
bath. Viability counts of antibiotic-containing
suspensions were performed at 0, 3, 6, 12 and
24 h by plating ten-fold dilutions of 0.1-mL
aliquots from each tube in sterile Haemophilus test
medium on to chocolate agar plates (BBL Micro-
biology Systems, Cockeysville, MD, USA). Recov-
ery plates were incubated for up to 48 h. Colony
counts were performed on plates yielding 30–300
colonies [10,15–17]. The lower limit of sensitivity
of colony counts was 300 CFU ⁄mL. Results were
analysed by determining the number of strains
that yielded a D log10 CFU ⁄mL of )1, )2 and )3
dilutions at each of the time-points, compared
with counts at 0 h. Antibacterial agents were
considered bactericidal at the lowest concentra-
tion that reduced the original inoculum by
‡ 3 · log10 CFU ⁄mL (99.9%) at each of the time-
points, and were considered bacteriostatic if the
inoculum was reduced by < 3 · CFU ⁄mL [10,15–
17]. MICs were determined by the macrobroth
method [18]. Erythromycin, azithromycin, clarith-
romycin and telithromycin kill kinetics were not
determined for the two strains with efﬂux sys-
tems plus ribosomal protein mutations.
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MICs for the strains tested are listed in Table 1,
and results of the time-kill experiments are shown
in Table 2. All quinoloneswere active against all 12
strains tested. Gemiﬂoxacin MICs were 0.001–
0.015 mg ⁄L, while ciproﬂoxacin, levoﬂoxacin, ga-
tiﬂoxacin and moxiﬂoxacin MICs were 0.008–
0.03 mg ⁄L. Macrolides and telithromycin gave
unimodal MICs (1.0–8.0 mg ⁄L), except for two
strains without efﬂux systems (0.0125–0.5 mg ⁄L)
and two strains with efﬂux systems and ribosomal
protein mutations (> 64.0 mg ⁄L).
All quinolones showed similar kill kinetics,
with bactericidal activity after 12 h at 2 · MIC for
seven to ten strains, and at 2 · MIC after 24 h for
all 12 strains. In comparison, erythromycin, azith-
romycin and clarithromycin were bactericidal
against eight to ten strains (excluding the two
strains with ribosomal protein mutations) at
Table 1. MICs (mg ⁄L) of 12 strains of Haemophilus inﬂuenzae
Drug
Phenotype
1 b-lac+,
MBL
2 b-lac+,
MBL
3 b-lac–,
MBL
4 b-lac–,
MBL
5 BLNAR,
MBL
6 BLNAR
MBL
7 BLPACR,
MBL
8 BLPACR,
MBL 9 MHS 10 MHS 11 MHR 12 MHR
Ciproﬂoxacin 0.015 0.015 0.008 0.015 0.015 0.015 0.008 0.015 0.008 0.008 0.008 0.008
Levoﬂoxacin 0.03 0.03 0.008 0.03 0.015 0.03 0.015 0.03 0.015 0.008 0.015 0.015
Gatiﬂoxacin 0.015 0.03 0.015 0.03 0.015 0.015 0.015 0.015 0.004 0.008 0.008 0.008
Moxiﬂoxacin 0.03 0.015 0.015 0.06 0.015 0.03 0.03 0.015 0.008 0.008 0.008 0.015
Gemiﬂoxacin 0.015 0.015 0.004 0.008 0.002 0.002 0.004 0.008 0.004 0.001 0.002 0.002
Erythromycin 8.0 8.0 4.0 8.0 4.0 4.0 4.0 4.0 0.5 0.25 > 64 > 64
Azithromycin 2.0 2.0 1.0 2.0 2.0 1.0 1.0 1.0 0.12 0.25 > 64 > 64
Clarithromycin 8.0 8.0 8.0 8.0 8.0 4.0 4.0 8.0 0.25 0.25 > 64 > 64
Telithromycin 2.0 2.0 1.0 1.0 2.0 4.0 1.0 2.0 0.12 0.12 > 64 > 64
b-lac+, b-lactamase-positive; b-lac–, b-lactamase-negative; BLNAR, b-lactamase-negative, ampicillin-resistant; BLPACR, b-lactamase-positive, amoxycillin–clavulanate-
resistant; MHS, macrolide-hyper-susceptible; MHR, macrolide-hyper-resistant; MBL, strains with ‘baseline’ macrolide MICs and efﬂux mechanisms.
Table 2. Number of Haemophilus inﬂuenzae strains yielding the indicated reduction in log10 CFU ⁄mL following incubation
Drug
3 h 6 h 12 h 24 h
90%
killing
99%
killing
99.9%
killing
90%
killing
99%
killing
99.9%
killing
90%
killing
99%
killing
99.9%
killing
90%
killing
99%
killing
99.9%
killing
Ciproﬂoxacin
4 · MIC 12 5 0 12 8 3 12 12 9 12 12 12
2 · MIC 12 2 0 12 5 1 12 12 9 12 12 12
MIC 4 1 0 12 1 1 12 12 4 12 11 11
Levoﬂoxacin
4 · MIC 12 7 1 12 10 4 12 12 10 12 12 12
2 · MIC 11 4 0 12 9 2 12 12 9 12 12 12
MIC 9 0 0 11 4 0 11 10 5 10 10 9
Gatiﬂoxacin
4 · MIC 12 9 2 12 12 5 12 12 12 12 12 12
2 · MIC 11 4 1 12 10 2 12 12 8 12 12 12
MIC 8 1 0 11 4 1 12 12 5 10 10 9
Moxiﬂoxacin
4 · MIC 12 8 4 12 11 7 12 12 11 12 12 12
2 · MIC 11 4 2 12 10 3 12 12 10 12 12 12
MIC 6 3 1 9 5 2 12 10 5 11 11 10
Gemiﬂoxacin
4 · MIC 12 2 0 12 8 2 12 12 10 12 12 12
2 · MIC 9 2 0 12 4 2 12 10 7 12 12 12
MIC 4 1 0 11 4 1 11 9 4 11 10 9
Erythromycina
4 · MIC 8 3 0 9 8 3 10 10 9 10 10 10
2 · MIC 5 0 0 9 5 2 10 8 6 10 9 8
MIC 3 0 0 7 2 0 8 6 5 9 8 7
Azithromycina
4 · MIC 9 5 1 10 9 5 10 10 10 10 10 10
2 · MIC 9 3 1 9 8 4 10 9 9 10 10 10
MIC 5 1 0 6 4 2 9 8 5 10 10 7
Clarithromycina
4 · MIC 7 2 0 9 7 2 10 10 8 10 10 10
2 · MIC 3 2 0 7 5 1 10 8 5 10 10 10
MIC 1 0 0 7 3 1 7 5 4 9 7 5
Telithromycina
4 · MIC 7 2 0 9 7 3 10 9 8 10 10 10
2 · MIC 5 1 0 9 5 0 10 9 6 10 10 10
MIC 3 0 0 6 3 0 10 6 3 9 9 8
aOnly ten of 12 strains tested.
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2 · MIC after 24 h, with bactericidal activity
against ﬁve to nine strains at 2 · MIC after 12 h.
Telithromycin was bactericidal against all ten
strains tested at 2 · MIC after 24 h, and against
six strains at 2 · MIC after 12 h.
The results demonstrate excellent activity, as
well as kill kinetics, for all quinolones tested
against all 12 H. inﬂuenzae strains tested, irres-
pective of their b-lactam or macrolide resistance
phenotype. Erythromycin, azithromycin, clarith-
romycin and telithromycin had unimodal MIC
distributions and good kill kinetics. The results
reﬂect those reported in previous studies of
H. inﬂuenzae strains with ‘baseline’ macrolide
susceptibility [10,15–17,19–21]. The differences of
opinion as to the clinical efﬁcacy of this group of
drugs against H. inﬂuenzae have been mentioned
above. In addition, the propensity of fully peni-
cillin-resistant (MIC > 2.0 mg ⁄L) pneumococcal
strains to be resistant to erythromycin, azithro-
mycin and clarithromycin [4] is another reason
why this group of drugs may not be ideal ﬁrst-
choice drugs for empirical therapy of community-
acquired respiratory tract infections in areas of
the world where drug-resistant pneumococci are
common. Typically, 75% of fully penicillin-resist-
ant strains are also resistant to macrolides [4].
Telithromycin, which has been licensed for use in
the USA, has lower MICs and better pharmaco-
kinetics and pharmacodynamics against macro-
lide-resistant pneumococci [15,17], but deﬁnitive
pharmacokinetic ⁄pharmacodynamic properties
and clinical efﬁcacy against H. inﬂuenzae have
not yet been established satisfactorily (W. A.
Craig, personal communication). Efﬂux mecha-
nisms for telithromycin, similar to those described
previously [12,13] for erythromycin, azithromycin
and clarithromycin, have recently been identiﬁed
in our laboratory (T. Bogdanovich et al., unpub-
lished results).
Broad-spectrum quinolones, such as gemiﬂoxa-
cin, levoﬂoxacin, gatiﬂoxacin and moxiﬂoxacin,
provide a more rational alternative, especially for
5-day treatment of acute exacerbations of chronic
bronchitis in the elderly [22], in which H. inﬂuen-
zae is the major pathogen [2,22]. Gemiﬂoxacin has
the added advantages of being very potent
against pneumococci, including many quino-
lone-resistant strains, and of targeting both pneu-
mococcal DNA gyrase and topoisomerase IV,
resulting, theoretically, in a lower likelihood of
selecting resistant mutants [22].
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ABSTRACT
Eighty isolates of Shigella spp. (37 Shigella ﬂexneri
and 43 Shigella sonnei) from patients with travel-
lers’ diarrhoea were studied. Susceptibility tests
revealed high levels of resistance, especially to
ampicillin (65%), tetracycline (78%) and trimeth-
oprim (75%), and particularly among the
S. ﬂexneri isolates. Dihydrofolate reductase 1
genes (dfrA1) were prevalent among the trimeth-
oprim-resistant isolates, while oxa genes predom-
inated among the ampicillin-resistant isolates.
Chloramphenicol resistance was associated with
production of chloramphenicol acetyltransferase,
while nalidixic acid-resistant isolates had a single
mutation in the gyrA gene. The results indicate a
continuing need for resistance surveillance and
rational use of antimicrobial agents.
Keywords Antimicrobial susceptibility, resistance
mechanisms, Shigella spp., surveillance, susceptibility
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The increase in intercontinental travel to exotic
destinations has resulted in infection by Shigella
spp. becoming an important cause of travellers’
diarrhoea (TD). Although the incidence of TD
caused by Shigella spp. is much lower than that of
TD caused by the main aetiological agent (i.e.,
enterotoxigenic Escherichia coli), Shigella causes a
more severe disease with greater morbidity. Fur-
thermore, Shigella spp. have been progressively
acquiring resistance to most of the antibiotics used
for the treatment of infections, partly because of
their ability to acquire resistance genes located on
plasmids or transposons [1]. However, other socio-
economic and behavioural factors have also con-
tributed to this increase in resistance [2]. Increased
international travel means that the appearance of
multiresistant pathogenic strains anywhere in the
world can rapidly become a public health problem
in other countries. Thus, the treatment decision for
shigellosis in developed countries is now com-
monly inﬂuenced by the patient’s travel history
[3]. The present report describes the susceptibility
patterns and mechanisms of resistance in Shigella
spp. with various geographical origins, isolated
from patients with TD.
Shigella isolates were obtained between 1995
and 2000 from the stool samples of patients
presenting with TD at the Hospital Clinic, Barce-
lona, Spain. Isolates were identiﬁed to the genus
and species level by conventional biochemical
methods [4] and agglutination with speciﬁc
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